Differential expression of IGF1R antisense noncoding RNA in hepatocellular carcinoma

doi:10.3969/j.issn.1004-583X.2021.07.009

Abstract

Abstract:

Objective To detect the difference of insulin-like growth factor 1 receptor(IGF1R) antisense noncoding RNA(IGF1RAIN RNA) content between hepatocellular carcinoma and normal hepatic tissues, and to verify its possibility as a characteristic marker of hepatocellular carcinoma.Methods Reverse transcriptase polymerase chain reaction(RT-PCR) was used to detect the expression of IGF1RAIN RNA in 30 cases of hepatocellular carcinoma tissues, adjacent tissues and 16 cases of normal hepatic tissues(adjacent to the resection margin of hepatic hemangioma and hepatic cyst). Combined with the clinical and pathological data, the relationship between the content and hepatocellular cancer was analyzed.Results The content of IGF1RAIN RNA was significantly lower in hepatocellular cancer than that in normal hepatic tissues and adjacent tissues (P<0.05); IGF1RAIN RNA was different in tumor size, tumor differentiation and pathological stage(P<0.05).Conclusion The content of IGF1RAIN RNA was significantly decreased in hepatocellular cancer. It may be a marker for early diagnosis of hepatocellular cancer.

Key words: liver neoplasms, somatomedins, reverse transcriptase polymerase chain reaction, RNA

CLC Number:

R735.7

Xie Zhihai, Zhou Zhicong, Gui Yuan, Sun Jingfeng. Differential expression of IGF1R antisense noncoding RNA in hepatocellular carcinoma[J]. Clinical Focus, 2021, 36(7): 620-622.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.07.009

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I7/620

Figures/Tables 2

References 16

[1]	方文敏, 周绪红, 杨双, 等. 肝癌HepG2细胞株胰岛素样生长因子1和表皮生长因子受体基因沉默后放疗增敏机制[J]. 解剖学杂志, 2012,35(3):309-313, 340.
[2]	孙京男. IGF1R相关长链非编码RNA-IGF1RNA在恶性肿瘤中的作用及机制研究[D]. 吉林大学, 2014.
[3]	Perez DS, Hoage TR, Pritchett JR, et al. Long,abundantly expressed non-coding transcripts are altered in cancer[J]. Hum Mol Genet, 2008,17(5):642-655. doi: 10.1093/hmg/ddm336 URL
[4]	Sun J, Li W, Sun Y, et al. A novel antisense long noncoding RNA within the IGFlR gene locus is imprinted in hematopoietic malignancies[J]. Nucleic Acids Res, 2014,42(15):9588-9601. doi: 10.1093/nar/gku549 URL
[5]	Kang L, Sun J, Wen X, et al. Aberrant allele-switch imprinting of a novel IGFl R intragenic antisense non-coding RNA in breast cancers[J]. Eur J Cancer, 2015,51(2):260-270. doi: 10.1016/j.ejca.2014.10.031 URL
[6]	张立, 王炜, 李孝斌, 等. ARID2在原发性肝癌中的表达及对细胞增殖与细胞周期的影响[J]. 山西医科大学学报, 2018,(2):103-107.
[7]	Hakuno F, Takahashi SI, Bikle DD, et al. IGF1 receptor signaling pathways[J]. J Mol Endocrinol, 2018,61(1):T69-T86. doi: 10.1530/JME-17-0311 URL
[8]	Wang H, Tang C, Na M, et al. miR-422a inhibits glioma proliferation and invasion by targeting IGF1 and IGF1R[J]. Oncol Res, 2017,25(2):187-194. doi: 10.3727/096504016X14732772150389 URL
[9]	Xu G, Chen W, Xie W, et al. The association between IGF1 gene 3'-UTR polymorphisms and cancer risk: a meta-analysis[J]. Medicine (Baltimore), 2018,97(51):e13829. doi: 10.1097/MD.0000000000013829 URL
[10]	Yang J, Liu L, Tao H, et al. MeCP2 silencing of LncRNA H19 controls hepatic stellate cell proliferation by targeting IGF1R[J]. Toxicology, 2016, 359-360:39-46. doi: 10.1016/j.tox.2016.06.016 URL
[11]	Lian Y, Wang J, Feng J, et al. Long non-coding RNA IGF1RNA suppresses apoptosis and promotes proliferation by binding to LSD1 and EZH2 in pancreatic cancer[J]. Tumour Biol, 2016,37(11):14929-14937. doi: 10.1007/s13277-016-5380-8 URL
[12]	Refaee Saeedi N, Aghamohammadian Sharbaf H, Asghari Ebrahimabad MJ, et al. Psychological consequences of breast cancer in Iran: a meta-analysis[J]. Iran J Public Health, 2019,48(5):816-824.
[13]	Pashaiefar H, Izadifard M, Yaghmaie M, et al. Low expression of long noncoding RNA IRAIN is associated with poor prognosis in non-M3 acute myeloid leukemia patients[J]. Genet Test Mol Biomarkers, 2018,22(5):288-294. doi: 10.1089/gtmb.2017.0281 URL
[14]	Vaquero J, Lobe C, Tahraoui S, et al. The IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma[J]. Clin Cancer Res, 2018,24(17):4282-4296. doi: 10.1158/1078-0432.CCR-17-3725 pmid: 29716918
[15]	Werner H, Sarfstein R, Bruchim I. Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy[J]. Expert Opin Investig Drugs, 2019,28(12):1101-1112. doi: 10.1080/13543784.2019.1694660 URL
[16]	De Giovanni C, Landuzzi L, Palladini A, et al. Cancer vaccines co-targeting HER2/Neu and IGF1R[J]. Cancers (Basel), 2019,11(4):517. doi: 10.3390/cancers11040517 URL

标本	例数	IGF1RNA含量
正常肝组织	16	4.49±2.06
癌旁组织	30	3.71±1.89^*
肝癌组织	30	2.01±0.92^*#
F值		14.637
P值		<0.01

标本	例数	IGF1RNA含量
正常肝组织	16	4.49±2.06
癌旁组织	30	3.71±1.89^*
肝癌组织	30	2.01±0.92^*#
F值		14.637
P值		<0.01

项目	例数	IGF1RNA含量	t值	P值
年龄
>65岁 <65岁	16 14	2.41±1.01 2.14±0.69	0.842	0.407
性别
男女	19 11	2.32±0.98 2.15±0.82	0.485	0.632
乙型肝炎史
有无	18 12	2.51±1.08 2.14±0.95	0.963	0.34
肿瘤大小
小肝癌大肝癌	24 6	1.79±0.61 1.21±0.53	2.130	0.004
分化程度
低分化中高分化	19 11	2.70±0.82 1.19±0.31	5.835	0.000
肿瘤分期
早期中晚期	18 12	1.81±0.72 2.93±1.03		0.003

项目	例数	IGF1RNA含量	t值	P值
年龄
>65岁 <65岁	16 14	2.41±1.01 2.14±0.69	0.842	0.407
性别
男女	19 11	2.32±0.98 2.15±0.82	0.485	0.632
乙型肝炎史
有无	18 12	2.51±1.08 2.14±0.95	0.963	0.34
肿瘤大小
小肝癌大肝癌	24 6	1.79±0.61 1.21±0.53	2.130	0.004
分化程度
低分化中高分化	19 11	2.70±0.82 1.19±0.31	5.835	0.000
肿瘤分期
早期中晚期	18 12	1.81±0.72 2.93±1.03		0.003